Jupiter Wellness (NASDAQ: JUPW), a developer of cannabidiol (“CBD”) based therapeutics and wellness products, today announced initiation of a clinical study of its CaniSun(TM) sunscreen lotion for the treatment of actinic keratosis (“AK”), the most common precancer that forms on the skin as a result of exposure to ultraviolet (“UV”) rays. The clinical study’s primary objective is to evaluate Canisun as a treatment for AK by reviewing the efficacy in both treatment and prophylaxis of patients. The study, to be conducted by Applied Biology (Irvine, California), will recruit an estimated 116 adults diagnosed with AK. “I am excited to work with Applied Biology in the clinical evaluation of Canisun, which may have the potential to offer relief from this side effect to patients’ exposure to UV rays,” said Brian John, CEO of Jupiter Wellness. “Initiating this AK study represents an important opportunity for Jupiter Wellness to obtain patient data and evaluate any potential benefits of our sunscreen products.”
To view the full press release, visit https://ibn.fm/0epQ7
About Jupiter Wellness Inc.
Jupiter Wellness is a leading developer of cannabidiol (“CBD”) based medical therapeutics and wellness products. The company’s clinical pipeline of prescription CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun(TM) sunscreen and other wellness brands sold through its robust distribution platform. For more information, visit the company’s website at www.JupiterWellnessInc.com.
NOTE TO INVESTORS: The latest news and updates relating to JUPW are available in the company’s newsroom at https://ibn.fm/JUPW
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.